There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Akoya Biosciences (AKYA – Research Report) with bullish sentiments.
Atricure (ATRC)
Piper Sandler analyst Matthew O’Brien assigned a Buy rating to Atricure on December 18 and set a price target of $65.00. The company’s shares closed last Wednesday at $34.48, close to its 52-week low of $32.27.
According to TipRanks.com, O’Brien is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atricure with a $55.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Akoya Biosciences (AKYA)
In a report issued on December 18, David Westenberg from Piper Sandler assigned a Buy rating to Akoya Biosciences, with a price target of $8.00. The company’s shares closed last Wednesday at $4.71.
According to TipRanks.com, Westenberg is a 3-star analyst with an average return of
Currently, the analyst consensus on Akoya Biosciences is a Strong Buy with an average price target of $9.00, representing a 92.7% upside. In a report issued on December 19, Canaccord Genuity also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATRC:
- AtriCure says ‘welcomes’ competition from Medtronic
- Medtronic launch could create an overhang on AtriCure, says Needham
- Medtronic launches Penditure Left Atrial Appendage Exclusion System in U.S.
- AtriCure price target lowered to $49 from $68 at Needham
- AtriCure price target lowered to $45 from $79 at Canaccord
